دورية أكاديمية
Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients
| العنوان: | Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients |
|---|---|
| المؤلفون: | S. Deffontaines-Rufin, M. Weil, D. Verollet, L. Peyrat, G. Amarenco |
| المصدر: | International Brazilian Journal of Urology, Vol 37, Iss 5, Pp 642-648 (2011) |
| بيانات النشر: | Sociedade Brasileira de Urologia, 2011. |
| سنة النشر: | 2011 |
| المجموعة: | LCC:Diseases of the genitourinary system. Urology |
| مصطلحات موضوعية: | kidney, multiple sclerosis, botulinum toxins, urinary bladder, neurogenic, administration, intravesical, treatment outcome, Diseases of the genitourinary system. Urology, RC870-923 |
| الوصف: | PURPOSE: Neurogenic detrusor overactivity (NDO) is common in patients who suffer from multiple sclerosis (MS). When the usual pharmacological treatment fails, botulinum toxin type A (BTX-A) injections can be proposed. The safety and efficacy of this treatment are already well known, but only a few studies focus on its use in patients with MS. MATERIALS AND METHODS: Seventy-one patients with MS underwent their first BTX-A injection for refractory NDO. They had clinical and urodynamic cystometry assessment before and three months after injection. The patients were divided in three groups according to treatment efficacy: full success (total urinary continence, no overactive detrusor), improvement, or total failure (urge incontinence and overactive detrusor). RESULTS: 77% of the patients had clinical improvement or full success of the treatment with a reduction of their urgency and incontinence. Significant urodynamic improvement after treatment was shown on different parameters: volume at first involuntary bladder contraction (p = 0.0000001), maximum cystometric capacity (p = 0.0035), maximum detrusor pressure (p = 0.0000001). 46% of the patients were in the "full success" group. 31% of the patients had a partial improvement. 23% of the patients had no efficacy of the treatment. Duration of MS was a predictive factor of treatment failure (p = 0.015). CONCLUSIONS: Despite that a full success was obtained in 46% of the cases, BTX-A injection therapy failed to treat refractory NDO in 23% of patients suffering from MS. Duration of the disease was a predictive factor for an inefficient treatment. The injection therapy should be considered as soon as oral anticholinergic drugs fail to reduce NDO. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1677-5538 1677-6119 |
| Relation: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382011000500012; https://doaj.org/toc/1677-5538; https://doaj.org/toc/1677-6119 |
| DOI: | 10.1590/S1677-55382011000500012 |
| URL الوصول: | https://doaj.org/article/630fd00c056e4e849bfccf92ec40389e |
| رقم الأكسشن: | edsdoj.630fd00c056e4e849bfccf92ec40389e |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 16775538 16776119 |
|---|---|
| DOI: | 10.1590/S1677-55382011000500012 |